


Communications to the editor

CHEMISTRY OF THE
STREPTOVARICINS. VI
OXIDATION PRODUCTS FROM
STREPTOVARICIN C*

Sir:

Intense recent interest has been generated in the ansamycins²⁾ as potential anti-viral agents: rifamycin derivatives³⁾ and streptovaricins⁴⁾ inhibit virus replication, other rifamycin derivatives inhibit DNA polymerase activities of RNA tumor viruses⁵⁾, the streptovaricins inhibit mouse leukemia virus⁶⁾. These biological results prompt us to report in this and the accompanying communication our recent structural results with streptovaricin C. In this report we describe oxidative degradation products whose structures necessitate a revision of the structure (1) earlier assigned¹⁾ to streptovaricin C [as well as a revision of that assigned then (1, but X=OH, Y=OAc) to streptovaricin A]. The accompanying manuscript assigns a revised structure to streptovaricin C⁷⁾, related work assigns structures to streptovaricins A, B, D, E, F, and G⁸⁾.

Oxidation of streptovaricin C triacetate¹⁾ with osmium tetroxide-sodium periodate for different periods of time gave the dialdehydes 2 [$C_{14}H_{18}O_4$ **], λ_{\max} 227, 270 nm; $\bar{\nu}$ 2700, 1725, 1690, 1610 cm^{-1} , no OH; *bis*-DNP



derivative, $C_{26}H_{26}N_8O_{10}$ **, m.p. 189~190°C] and 4 [$C_{18}H_{24}O_6$ **], λ_{\max} 222, 268 nm; $\bar{\nu}$ 2700, 1735, 1720, 1680, 1620 cm^{-1}], whose nmr spectra are summarized in Fig. 1. Reduction of these compounds with sodium borohydride gave 3 [$C_{14}H_{22}O_4$ **], λ_{\max} 210 nm (end absorption), 230 nm (inflection); $\bar{\nu}$ 3400~3350, 1710, 1620 cm^{-1}] and 5 [$C_{18}H_{28}O_6$ ***], λ_{\max}^{EtOH} 214, 236 nm (ϵ 10,200, 7800 inflection); $\bar{\nu}_{CHCl_3}$ 3600~3300, 1725 (broad) cm^{-1}]. Further reduction of 5 with lithium aluminum hydride gave 6 [$C_{18}H_{26}O_4$ ***], λ_{\max}^{EtOH} 232 nm (ϵ 9300); $\bar{\nu}$ 3500~3100 cm^{-1}]. A related oxidative degradation product(7) was obtained in four steps from streptovaricin C, whose treatment with periodate (one mole consumption) gave streptovaricin C ($C_{40}H_{49}NO_{14}$ †, mp 140~143°C), containing the side chain system (C-1' to C-5') common to streptovarone and prestreptovarone^{7,8,9)}. Acetylation of streptovaricin C gave its triacetate ($C_{46}H_{55}NO_{17}$ †, m.p. 122~124°C), which on oxidation with osmium tetroxide-hydrogen peroxide, followed by oxidation with periodate, gave 7, a yellow oil ($C_{22}H_{32}O_{10}$ ***, end absorption <222 nm; $\bar{\nu}$ 1745 cm^{-1} , no OH).

These oxidation products, especially 7, are all clearly derived from the portion of streptovaricin C related to varicinal A^{10)††} formed from two-mole periodate cleavage of streptovaricin A (which contains a C-6 hydroxyl)-between C-6 and C-7 and between C-13 and the streptovarone side chain. However, the carbon chains of 2, 4 and 7 are extended toward the streptovaricin dienamide system (C-1 to C-5)^{1,7)} since streptovaricin C contains no C-6 hydroxyl for periodate cleavage¹⁾.

Structures 2, 4, and 7 obviously demand a revision of the structure (1) previously assigned streptovaricin C since they contain a carbomethoxyl group, while 1 does not^{†††}. This group is required by the infrared

* Presented in part at the 161st National Meeting of the American Chemical Society, Los Angeles, Calif., March-April, 1971; Abstracts, ORGN 111.

** Low resolution mass spectral data agree with the molecular formula assigned.

*** Microanalyses and low resolution mass spectral data agree with the molecular formula assigned.

† Microanalyses agree with the molecular formula assigned.

†† The structure formerly assigned to varicinal A (8a)¹⁰⁾ can now be revised to 8b.

††† Structure 1 was based in large measure on the structure (8a) earlier assigned to varicinal A, in which the carbomethoxyl group was not detected¹⁰⁾.





Fig. 1. Chemical shifts and multiplicities of protons in nmr spectra (CDCl_3) of compounds discussed.

Abbreviations of multiplicities are: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, b=broad. Funds contributing to the purchase of the HA 220 nmr spectrometer were provided by the National Science Foundation.



carbonyl absorption (1710 cm^{-1}) of **3** and by the ultraviolet unsaturated ester absorption of **5** (214 nm , $\epsilon\ 10,200$), lacking in **6**. The carbomethoxy group is located conclusively from the nmr chemical shift and coupling patterns of **2**~**7**, as well as by the nmr data for streptovaricin C itself⁸. The structure of compound **7** juxtaposes the carbomethoxy and the other substituents of the side chain. Their positions agree with earlier studies^{1,10}.

A final important oxidation product is **9**, obtained by oxidation of streptovaricin C tetraacetate [$\text{C}_{48}\text{H}_{59}\text{NO}_{18}$ *, m.p. $180\sim 182^\circ\text{C}$] with ruthenium tetroxide¹¹ in aqueous acetone at room temperature, followed by methylation of the product with diazomethane. The structure of compound **9** [$\text{C}_{25}\text{H}_{38}\text{O}_{13}$ †, colorless oil, bp 180°C (0.05 Torr); end absorption $<210\text{ nm}$, weak $\lambda_{\text{max}}\ 280\text{ nm}$; $\bar{\nu}\ 1735, 1715\text{ (sh)}\text{ cm}^{-1}$, no hydroxyl absorption; positive 2,4-DNP test] was assigned from its 220 MHz nmr spectrum and from spin decoupling of its 100 MHz spectrum, as summarized in Fig. 1.

The structure assigned (**9**) establishes that C-13 of the aliphatic chain is attached in streptovaricin C to a methyl-

* Microanalyses and low resolution mass spectral data agree with the molecular formula assigned.

† Microanalyses, low resolution mass spectral data, and high resolution mass spectral data agree with the molecular formula assigned.

bearing carbon (in fact, C-4')⁷⁾ in the side chain of streptovarone. The ramifications of that linkage allow the assignment of a structure to streptovaricin C but require a revision of the previously assigned structures of streptovaricin C and streptovarone, as discussed in the accompanying communication⁷⁾.

Acknowledgment

This investigation was supported in part by PHS Research Grants AI 01278 and AI 04769 from the National Institute of Allergy and Infectious Diseases and CA 11388 from the National Cancer Institute.

KAZUYA SASAKI
KENNETH L. RINEHART, Jr.
FREDERICK J. ANTOSZ*

Department of Chemistry,
University of Illinois,
Urbana, Illinois 61801, U.S.A.

(Received October 15, 1971)

References

- 1) PAPER, V.; RINEHART, JR., K.L., H.H. MATHUR, K. SASAKI, P. K. MARTIN & C. E. COVERDALE: Chemistry of the streptovaricins. V. Structures of streptovaricins A and C. *J. Amer. Chem. Soc.* 90: 6241~6243, 1968
- 2) A review: RINEHART, JR., K. L.: Antibiotics with ansa rings. *Accts. Chem. Research* (in press.)
- 3) *i.a.*, HELLER, E.; M. ARGAMAN, H. LEVY & N. GOLDBLUM: Selective inhibition of vaccinia virus by the antibiotic rifampicin. *Nature* 222: 273~274, 1969
McAUSLAN, B. R.: Rifampicin inhibition of vaccinia replication. *Biochem. Biophys. Res. Comm.* 37: 289~295, 1969
MOSS, B.; E. N. ROSENBLUM, E. KATZ & P. M. GRIMLEY: Rifampicin: a specific inhibitor of vaccinia virus assembly. *Nature* 224: 1280~1284, 1969
SUBAK-SHARPE, J.H.; M. C. TIMBURY & J. F. WILLIAMS: Rifampicin inhibits the growth of some mammalian viruses. *Nature* 222: 341~345, 1969
ZAKAY-RONES, Z. & Y. BECKER: Anti-poxvirus activity of rifampicin associated with hydrazine side chain. *Nature* 226: 1162~1163, 1970
NAGAYAMA, A.; B. G. T. POGO & S. DALES: Biogenesis of vaccinia: separation of early stages from maturation by means of rifampicin. *Virology* 40: 1039~1051, 1970
FOLLETT, E. A. C. & T. H. PENNINGTON: Antiviral effect of constituent parts of the rifampicin molecule. *Nature* 230: 117~118, 1971
- 4) QUINTRELL, N. A. & B. R. McAUSLAN: Inhibition of poxvirus replication by streptovaricin. *J. Virol.* 6: 485~491, 1970
- 5) GURGO, C.; R. K. RAY, L. THIRY & M. GREEN: Inhibitors of the RNA and DNA dependent polymerase activities of RNA tumor viruses. *Nature (New Biology)* 229: 111~114, 1971
- 6) BROCKMAN, W. W.; W. A. CARTER, L.-H. LI, F. REUSSER & F. R. NICHOL: Streptovaricins inhibit RNA dependent DNA polymerase present in an oncogenic RNA virus. *Nature* 230: 249~250, 1971
- 7) RINEHART JR., K. L. & F. J. ANTOSZ: Chemistry of the streptovaricins. VII. Revised structures for streptovarone and streptovaricin C. *J. Antibiotics* 25: 71~73, 1972
- 8) RINEHART, JR., K. L.; M. L. MAHESHWARI, K. SASAKI, R. J. SCHACHT, H. H. MATHUR & F. J. ANTOSZ: Chemistry of the streptovaricins. VIII. Structures of streptovaricins A, B, D, E, F, and G. *J. Amer. Chem. Soc.* 93: 6273~6274, 1971
- 9) RINEHART, JR., K. L.; C. E. COVERDALE & P. K. MARTIN: Chemistry of the streptovaricins. II. Streptovarone and prestreptovarone. *J. Amer. Chem. Soc.* 88: 3150~3152, 1966
- 10) RINEHART, JR., K. L. & H. H. MATHUR: Chemistry of the streptovaricins. IV. Structure of varicinal A. *J. Amer. Chem. Soc.* 90: 6240, 1968
- 11) PIATAK, D. M.; H. B. BHAT & E. CASPI: Oxidation of steroidal ketones. VII. Cleavage of steroidal conjugated ketones with ruthenium tetroxide. *J. Org. Chem.* 34: 112~116, 1969

* Recipient of an NIH Postdoctoral Fellowship (AI 43866) from the National Institute of Allergy and Infectious Diseases.